Post Doctoral - Drug Metabolism and Clinical Safety
Boehringer Ingelheim
Summary
Boehringer Ingelheim is seeking a motivated, enthusiastic, and creative Post-Doctoral Fellow to join our Clinical Safety team located in Athens, GA. This position is part of the global Boehringer Ingelheim Post-Doctoral Program.
Job description
As a Post-Doctoral Fellow, you will be a primary driver of developing and applying assays to uncover the drug metabolism (DM) of pharmaceuticals, supporting the discovery and development of novel treatments for various animal health diseases.
We are looking for candidates with strong skills and interests in Molecular, Cellular, Analytical Chemistry, Biochemistry or similar field in Pharmaceutical Sciences, and experience in multidisciplinary research approaches. Post-Doctoral Fellows are expected to independently conduct research and publish findings in peer-reviewed scientific journals.
Duties & Responsibilities
- Lead a research project with guidance from experienced mentors with extensive backgrounds in academia and industry
- Contribute to the creation, organization, and execution of a research project
- Collaborate effectively with multi-disciplinary project teams
- Publish research findings in peer-reviewed scientific journals and present data at scientific conferences
- Ensure compliance with all applicable regulations, performing all work safely and maintaining proper records in accordance with SOPs and policies
Requirements
- PhD degree or equivalent in Molecular, Cellular or Biochemistry or similar field, with good publications record
- Ability to work independently
- Ability to design and execute experimental strategy to advance projects
- Demonstrated creativity and novel approaches to solving scientific problems
- Excellent written and oral communication skills
Eligibility Requirements
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
Desired Skills, Experience and Abilities
- Demonstrated creativity and initiative in driving cutting edge research
- Demonstrated knowledge and hands-on experience in cell biology, HPLC and qPCR etc, Experience with LC-MS or metabolite identification is a plus
- Basic knowledge of drug metabolism, drug metabolizing enzymes and drug-drug interaction, ability to ask critical scientific questions, synthesize new hypotheses and critique devised hypotheses
Requirements
- PhD degree or equivalent in Molecular, Cellular or Biochemistry or similar field, with good publications record
- Ability to work independently
- Ability to design and execute experimental strategy to advance projects
- Demonstrated creativity and novel approaches to solving scientific problems
- Excellent written and oral communication skills
- Must be legally authorized to work in the United States without restriction
- Must be willing to take a drug test and post-offer physical (if required)
- Must be 18 years of age or older
- Demonstrated knowledge and hands-on experience in cell biology, HPLC and qPCR
- Experience with LC-MS or metabolite identification is a plus
- Basic knowledge of drug metabolism, drug metabolizing enzymes and drug-drug interaction
Company overview
Boehringer Ingelheim is a leading global research-driven biopharmaceutical company founded in 1885 and headquartered in Ingelheim am Rhein, Germany. As one of the world's top 20 pharmaceutical companies and the largest privately-owned pharmaceutical firm, it operates across three main business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. The company focuses on developing innovative therapies for diseases with high unmet medical needs, including cardiometabolic diseases, oncology, respiratory diseases, immunology, central nervous system disorders, and retinal health. With over 54,500 employees across 78 countries, Boehringer Ingelheim generated approximately €26.8 billion in revenue in 2024. The company maintains a strong research and development network with facilities in Germany, the United States, Austria, Japan, and Switzerland, investing significantly in advancing treatments for both human and animal health. Notable products include Jardiance (empagliflozin) for diabetes, Ofev (nintedanib) for pulmonary fibrosis, Spiriva (tiotropium) for respiratory conditions, and Pradaxa (dabigatran) for anticoagulation therapy.